Global Vasomotor Symptoms Treatment Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029
1 Market Overview
- 1.1 Product Overview and Scope of Vasomotor Symptoms Treatment
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Market Analysis by Type
- 1.3.1 Overview: Global Vasomotor Symptoms Treatment Consumption Value by Type: 2018 Versus 2022 Versus 2029
- 1.3.2 Hormonal Therapies
- 1.3.3 Non-Hormonal Therapies
- 1.3.4 Others
- 1.4 Market Analysis by Application
- 1.4.1 Overview: Global Vasomotor Symptoms Treatment Consumption Value by Application: 2018 Versus 2022 Versus 2029
- 1.4.2 Clinic
- 1.4.3 Hospital
- 1.4.4 Others
- 1.5 Global Vasomotor Symptoms Treatment Market Size & Forecast
- 1.5.1 Global Vasomotor Symptoms Treatment Consumption Value (2018 & 2022 & 2029)
- 1.5.2 Global Vasomotor Symptoms Treatment Sales Quantity (2018-2029)
- 1.5.3 Global Vasomotor Symptoms Treatment Average Price (2018-2029)
2 Manufacturers Profiles
- 2.1 Bayer AG
- 2.1.1 Bayer AG Details
- 2.1.2 Bayer AG Major Business
- 2.1.3 Bayer AG Vasomotor Symptoms Treatment Product and Services
- 2.1.4 Bayer AG Vasomotor Symptoms Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
- 2.1.5 Bayer AG Recent Developments/Updates
- 2.2 Fervent Pharmaceuticals, LLC
- 2.2.1 Fervent Pharmaceuticals, LLC Details
- 2.2.2 Fervent Pharmaceuticals, LLC Major Business
- 2.2.3 Fervent Pharmaceuticals, LLC Vasomotor Symptoms Treatment Product and Services
- 2.2.4 Fervent Pharmaceuticals, LLC Vasomotor Symptoms Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
- 2.2.5 Fervent Pharmaceuticals, LLC Recent Developments/Updates
- 2.3 Astellas Pharma Inc.
- 2.3.1 Astellas Pharma Inc. Details
- 2.3.2 Astellas Pharma Inc. Major Business
- 2.3.3 Astellas Pharma Inc. Vasomotor Symptoms Treatment Product and Services
- 2.3.4 Astellas Pharma Inc. Vasomotor Symptoms Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
- 2.3.5 Astellas Pharma Inc. Recent Developments/Updates
- 2.4 Frazier Healthcare Partners
- 2.4.1 Frazier Healthcare Partners Details
- 2.4.2 Frazier Healthcare Partners Major Business
- 2.4.3 Frazier Healthcare Partners Vasomotor Symptoms Treatment Product and Services
- 2.4.4 Frazier Healthcare Partners Vasomotor Symptoms Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
- 2.4.5 Frazier Healthcare Partners Recent Developments/Updates
- 2.5 Mitsubishi Tanabe Pharma Corporation
- 2.5.1 Mitsubishi Tanabe Pharma Corporation Details
- 2.5.2 Mitsubishi Tanabe Pharma Corporation Major Business
- 2.5.3 Mitsubishi Tanabe Pharma Corporation Vasomotor Symptoms Treatment Product and Services
- 2.5.4 Mitsubishi Tanabe Pharma Corporation Vasomotor Symptoms Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
- 2.5.5 Mitsubishi Tanabe Pharma Corporation Recent Developments/Updates
- 2.6 Eli Lilly and Company
- 2.6.1 Eli Lilly and Company Details
- 2.6.2 Eli Lilly and Company Major Business
- 2.6.3 Eli Lilly and Company Vasomotor Symptoms Treatment Product and Services
- 2.6.4 Eli Lilly and Company Vasomotor Symptoms Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
- 2.6.5 Eli Lilly and Company Recent Developments/Updates
- 2.7 AbbVie Inc.
- 2.7.1 AbbVie Inc. Details
- 2.7.2 AbbVie Inc. Major Business
- 2.7.3 AbbVie Inc. Vasomotor Symptoms Treatment Product and Services
- 2.7.4 AbbVie Inc. Vasomotor Symptoms Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
- 2.7.5 AbbVie Inc. Recent Developments/Updates
- 2.8 AMAG Pharmaceuticals Inc.
- 2.8.1 AMAG Pharmaceuticals Inc. Details
- 2.8.2 AMAG Pharmaceuticals Inc. Major Business
- 2.8.3 AMAG Pharmaceuticals Inc. Vasomotor Symptoms Treatment Product and Services
- 2.8.4 AMAG Pharmaceuticals Inc. Vasomotor Symptoms Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
- 2.8.5 AMAG Pharmaceuticals Inc. Recent Developments/Updates
- 2.9 Emcure Pharmaceuticals Limited
- 2.9.1 Emcure Pharmaceuticals Limited Details
- 2.9.2 Emcure Pharmaceuticals Limited Major Business
- 2.9.3 Emcure Pharmaceuticals Limited Vasomotor Symptoms Treatment Product and Services
- 2.9.4 Emcure Pharmaceuticals Limited Vasomotor Symptoms Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
- 2.9.5 Emcure Pharmaceuticals Limited Recent Developments/Updates
- 2.10 Merck & Co., Inc.
- 2.10.1 Merck & Co., Inc. Details
- 2.10.2 Merck & Co., Inc. Major Business
- 2.10.3 Merck & Co., Inc. Vasomotor Symptoms Treatment Product and Services
- 2.10.4 Merck & Co., Inc. Vasomotor Symptoms Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
- 2.10.5 Merck & Co., Inc. Recent Developments/Updates
- 2.11 Novartis AG
- 2.11.1 Novartis AG Details
- 2.11.2 Novartis AG Major Business
- 2.11.3 Novartis AG Vasomotor Symptoms Treatment Product and Services
- 2.11.4 Novartis AG Vasomotor Symptoms Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
- 2.11.5 Novartis AG Recent Developments/Updates
- 2.12 Novo Nordisk A/S
- 2.12.1 Novo Nordisk A/S Details
- 2.12.2 Novo Nordisk A/S Major Business
- 2.12.3 Novo Nordisk A/S Vasomotor Symptoms Treatment Product and Services
- 2.12.4 Novo Nordisk A/S Vasomotor Symptoms Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
- 2.12.5 Novo Nordisk A/S Recent Developments/Updates
- 2.13 Pfizer Inc.
- 2.13.1 Pfizer Inc. Details
- 2.13.2 Pfizer Inc. Major Business
- 2.13.3 Pfizer Inc. Vasomotor Symptoms Treatment Product and Services
- 2.13.4 Pfizer Inc. Vasomotor Symptoms Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
- 2.13.5 Pfizer Inc. Recent Developments/Updates
- 2.14 Teva Pharmaceutical Industries Ltd.
- 2.14.1 Teva Pharmaceutical Industries Ltd. Details
- 2.14.2 Teva Pharmaceutical Industries Ltd. Major Business
- 2.14.3 Teva Pharmaceutical Industries Ltd. Vasomotor Symptoms Treatment Product and Services
- 2.14.4 Teva Pharmaceutical Industries Ltd. Vasomotor Symptoms Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
- 2.14.5 Teva Pharmaceutical Industries Ltd. Recent Developments/Updates
3 Competitive Environment: Vasomotor Symptoms Treatment by Manufacturer
- 3.1 Global Vasomotor Symptoms Treatment Sales Quantity by Manufacturer (2018-2023)
- 3.2 Global Vasomotor Symptoms Treatment Revenue by Manufacturer (2018-2023)
- 3.3 Global Vasomotor Symptoms Treatment Average Price by Manufacturer (2018-2023)
- 3.4 Market Share Analysis (2022)
- 3.4.1 Producer Shipments of Vasomotor Symptoms Treatment by Manufacturer Revenue ($MM) and Market Share (%): 2022
- 3.4.2 Top 3 Vasomotor Symptoms Treatment Manufacturer Market Share in 2022
- 3.4.2 Top 6 Vasomotor Symptoms Treatment Manufacturer Market Share in 2022
- 3.5 Vasomotor Symptoms Treatment Market: Overall Company Footprint Analysis
- 3.5.1 Vasomotor Symptoms Treatment Market: Region Footprint
- 3.5.2 Vasomotor Symptoms Treatment Market: Company Product Type Footprint
- 3.5.3 Vasomotor Symptoms Treatment Market: Company Product Application Footprint
- 3.6 New Market Entrants and Barriers to Market Entry
- 3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
- 4.1 Global Vasomotor Symptoms Treatment Market Size by Region
- 4.1.1 Global Vasomotor Symptoms Treatment Sales Quantity by Region (2018-2029)
- 4.1.2 Global Vasomotor Symptoms Treatment Consumption Value by Region (2018-2029)
- 4.1.3 Global Vasomotor Symptoms Treatment Average Price by Region (2018-2029)
- 4.2 North America Vasomotor Symptoms Treatment Consumption Value (2018-2029)
- 4.3 Europe Vasomotor Symptoms Treatment Consumption Value (2018-2029)
- 4.4 Asia-Pacific Vasomotor Symptoms Treatment Consumption Value (2018-2029)
- 4.5 South America Vasomotor Symptoms Treatment Consumption Value (2018-2029)
- 4.6 Middle East and Africa Vasomotor Symptoms Treatment Consumption Value (2018-2029)
5 Market Segment by Type
- 5.1 Global Vasomotor Symptoms Treatment Sales Quantity by Type (2018-2029)
- 5.2 Global Vasomotor Symptoms Treatment Consumption Value by Type (2018-2029)
- 5.3 Global Vasomotor Symptoms Treatment Average Price by Type (2018-2029)
6 Market Segment by Application
- 6.1 Global Vasomotor Symptoms Treatment Sales Quantity by Application (2018-2029)
- 6.2 Global Vasomotor Symptoms Treatment Consumption Value by Application (2018-2029)
- 6.3 Global Vasomotor Symptoms Treatment Average Price by Application (2018-2029)
7 North America
- 7.1 North America Vasomotor Symptoms Treatment Sales Quantity by Type (2018-2029)
- 7.2 North America Vasomotor Symptoms Treatment Sales Quantity by Application (2018-2029)
- 7.3 North America Vasomotor Symptoms Treatment Market Size by Country
- 7.3.1 North America Vasomotor Symptoms Treatment Sales Quantity by Country (2018-2029)
- 7.3.2 North America Vasomotor Symptoms Treatment Consumption Value by Country (2018-2029)
- 7.3.3 United States Market Size and Forecast (2018-2029)
- 7.3.4 Canada Market Size and Forecast (2018-2029)
- 7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
- 8.1 Europe Vasomotor Symptoms Treatment Sales Quantity by Type (2018-2029)
- 8.2 Europe Vasomotor Symptoms Treatment Sales Quantity by Application (2018-2029)
- 8.3 Europe Vasomotor Symptoms Treatment Market Size by Country
- 8.3.1 Europe Vasomotor Symptoms Treatment Sales Quantity by Country (2018-2029)
- 8.3.2 Europe Vasomotor Symptoms Treatment Consumption Value by Country (2018-2029)
- 8.3.3 Germany Market Size and Forecast (2018-2029)
- 8.3.4 France Market Size and Forecast (2018-2029)
- 8.3.5 United Kingdom Market Size and Forecast (2018-2029)
- 8.3.6 Russia Market Size and Forecast (2018-2029)
- 8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
- 9.1 Asia-Pacific Vasomotor Symptoms Treatment Sales Quantity by Type (2018-2029)
- 9.2 Asia-Pacific Vasomotor Symptoms Treatment Sales Quantity by Application (2018-2029)
- 9.3 Asia-Pacific Vasomotor Symptoms Treatment Market Size by Region
- 9.3.1 Asia-Pacific Vasomotor Symptoms Treatment Sales Quantity by Region (2018-2029)
- 9.3.2 Asia-Pacific Vasomotor Symptoms Treatment Consumption Value by Region (2018-2029)
- 9.3.3 China Market Size and Forecast (2018-2029)
- 9.3.4 Japan Market Size and Forecast (2018-2029)
- 9.3.5 Korea Market Size and Forecast (2018-2029)
- 9.3.6 India Market Size and Forecast (2018-2029)
- 9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
- 9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
- 10.1 South America Vasomotor Symptoms Treatment Sales Quantity by Type (2018-2029)
- 10.2 South America Vasomotor Symptoms Treatment Sales Quantity by Application (2018-2029)
- 10.3 South America Vasomotor Symptoms Treatment Market Size by Country
- 10.3.1 South America Vasomotor Symptoms Treatment Sales Quantity by Country (2018-2029)
- 10.3.2 South America Vasomotor Symptoms Treatment Consumption Value by Country (2018-2029)
- 10.3.3 Brazil Market Size and Forecast (2018-2029)
- 10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
- 11.1 Middle East & Africa Vasomotor Symptoms Treatment Sales Quantity by Type (2018-2029)
- 11.2 Middle East & Africa Vasomotor Symptoms Treatment Sales Quantity by Application (2018-2029)
- 11.3 Middle East & Africa Vasomotor Symptoms Treatment Market Size by Country
- 11.3.1 Middle East & Africa Vasomotor Symptoms Treatment Sales Quantity by Country (2018-2029)
- 11.3.2 Middle East & Africa Vasomotor Symptoms Treatment Consumption Value by Country (2018-2029)
- 11.3.3 Turkey Market Size and Forecast (2018-2029)
- 11.3.4 Egypt Market Size and Forecast (2018-2029)
- 11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
- 11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
- 12.1 Vasomotor Symptoms Treatment Market Drivers
- 12.2 Vasomotor Symptoms Treatment Market Restraints
- 12.3 Vasomotor Symptoms Treatment Trends Analysis
- 12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry
- 12.5 Influence of COVID-19 and Russia-Ukraine War
- 12.5.1 Influence of COVID-19
- 12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
- 13.1 Raw Material of Vasomotor Symptoms Treatment and Key Manufacturers
- 13.2 Manufacturing Costs Percentage of Vasomotor Symptoms Treatment
- 13.3 Vasomotor Symptoms Treatment Production Process
- 13.4 Vasomotor Symptoms Treatment Industrial Chain
14 Shipments by Distribution Channel
- 14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
- 14.2 Vasomotor Symptoms Treatment Typical Distributors
- 14.3 Vasomotor Symptoms Treatment Typical Customers
15 Research Findings and Conclusion
16 Appendix
- 16.1 Methodology
- 16.2 Research Process and Data Source
According to our (Global Info Research) latest study, the global Vasomotor Symptoms Treatment market size was valued at USD 9065 million in 2022 and is forecast to a readjusted size of USD 12570 million by 2029 with a CAGR of 4.8% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
This report is a detailed and comprehensive analysis for global Vasomotor Symptoms Treatment market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Vasomotor Symptoms Treatment market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Vasomotor Symptoms Treatment market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Vasomotor Symptoms Treatment market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Vasomotor Symptoms Treatment market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Vasomotor Symptoms Treatment
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Vasomotor Symptoms Treatment market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bayer AG, Fervent Pharmaceuticals, LLC, Astellas Pharma Inc., Frazier Healthcare Partners and Mitsubishi Tanabe Pharma Corporation, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Vasomotor Symptoms Treatment market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Hormonal Therapies
Non-Hormonal Therapies
Others
Market segment by Application
Clinic
Hospital
Others
Major players covered
Bayer AG
Fervent Pharmaceuticals, LLC
Astellas Pharma Inc.
Frazier Healthcare Partners
Mitsubishi Tanabe Pharma Corporation
Eli Lilly and Company
AbbVie Inc.
AMAG Pharmaceuticals Inc.
Emcure Pharmaceuticals Limited
Merck & Co., Inc.
Novartis AG
Novo Nordisk A/S
Pfizer Inc.
Teva Pharmaceutical Industries Ltd.
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Vasomotor Symptoms Treatment product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Vasomotor Symptoms Treatment, with price, sales, revenue and global market share of Vasomotor Symptoms Treatment from 2018 to 2023.
Chapter 3, the Vasomotor Symptoms Treatment competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Vasomotor Symptoms Treatment breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Vasomotor Symptoms Treatment market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Vasomotor Symptoms Treatment.
Chapter 14 and 15, to describe Vasomotor Symptoms Treatment sales channel, distributors, customers, research findings and conclusion.